Literature DB >> 8017641

Renal concentrating function with prolonged sevoflurane or enflurane anesthesia in volunteers.

E J Frink1, T P Malan, R J Isner, E A Brown, S E Morgan, B R Brown.   

Abstract

BACKGROUND: Sevoflurane, a new inhalational anesthetic, is biotransformed, producing peak plasma inorganic fluoride concentrations that may exceed 50 microM. We evaluated plasma inorganic fluoride concentrations with prolonged (> 9 MAC-h) sevoflurane or enflurane anesthesia in volunteers and compared renal concentrating function with desmopressin testing 1 and 5 days after anesthesia.
METHODS: Fourteen healthy male volunteers received either enflurane or sevoflurane (1-1.2 MAC) for more than 9 MAC-h. Each volunteer was administered three tests of renal concentrating function, with intranasal desmopressin and urine collections performed 1 week before anesthesia and 1 and 5 days after anesthesia. Venous blood samples were obtained for plasma fluoride concentrations during and after anesthesia. Creatinine clearance was determined by 24-h urine collections 7 days before and 4 days after anesthesia. Urine samples were obtained before and 1, 2, and 5 days after anesthesia for determination of n-acetyl-beta-glucosaminidase and creatinine concentrations.
RESULTS: Prolonged sevoflurane anesthesia (9.5 MAC-h) did not impair renal concentrating function on day 1 or 5 postanesthesia, as determined by desmopressin testing. Maximal urinary osmolality on day 1 postanesthesia was decreased (< 800 mOsm/kg) in two of seven enflurane-anesthetized volunteers; however, mean results did not differ from the those of the sevoflurane group. Mean peak plasma fluoride ion concentrations were 23 +/- 1 microM 6 h postanesthesia for enflurane and 47 +/- 3 microM at the end of anesthesia for sevoflurane (P < 0.01). There were no changes in creatinine clearance or urinary n-acetyl-beta-glucosaminidase concentration in either anesthetic group. DISCUSSION: Prolonged sevoflurane anesthesia did not impair renal concentrating function, as evaluated with desmopressin testing 1 and 5 days postanesthesia in healthy volunteers. Although with prolonged enflurane anesthesia, mean maximal osmolality values on day 1 postanesthesia did not differ from sevoflurane values, there was evidence in two volunteers at this time point of impairment in renal concentrating function, which normalized 5 days postanesthesia. These results occurred despite a higher peak plasma fluoride ion concentration and greater total inorganic fluoride renal exposure with sevoflurane anesthesia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017641     DOI: 10.1097/00000542-199405000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  Inorganic fluoride. Divergent effects on human proximal tubular cell viability.

Authors:  R A Zager; M Iwata
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Pharmacokinetics of fluoride in toddlers after application of 5% sodium fluoride dental varnish.

Authors:  Peter Milgrom; Donald M Taves; Amy S Kim; Gene E Watson; Jeremy A Horst
Journal:  Pediatrics       Date:  2014-08-18       Impact factor: 7.124

3.  Comparison of sevoflurane/fentanyl and isoflurane/fentanyl during elective coronary artery bypass surgery. Sevoflurane Venture Group.

Authors:  N R Searle; R J Martineau; P Conzen; A al-Hasani; L Mark; T Ebert; M Muzi; L R Hodgins
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

4.  Effect of sevoflurane anesthesia on the severity of renal histopathologic changes in rabbits pretreated with gentamicin: A controlled, investigator-blinded, experimental study.

Authors:  Azize Bestas; Mustafa Kemal Bayar; Nusret Akpolat; Mehmet Nihat Okuducu
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

Review 5.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 6.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 7.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 9.  [Volatile anesthetics].

Authors:  M Loscar; P Conzen
Journal:  Anaesthesist       Date:  2004-02       Impact factor: 1.041

10.  Anesthetic management of a patient with Bartter's syndrome undergoing bilateral sagittal split osteotomy.

Authors:  Nasser Nooh; Walid Abdullah; Saad Sheta
Journal:  Saudi J Anaesth       Date:  2012 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.